|Day Low/High||111.33 / 113.82|
|52 Wk Low/High||101.36 / 132.13|
Let's step back and look at the bigger picture through charts and indicators.
Jim Cramer says spotting the bottom is really tough; and if you're too early, you'll get hit hard.
I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.
INDIANAPOLIS, June 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the company will present positive, five-year Phase 3 data for Taltz ® (ixekizumab).
- CAROLINA® demonstrated no increased cardiovascular risk for Tradjenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor
- Findings from an EMPA-REG OUTCOME® post-hoc analysis of adults with chronic kidney disease without overt proteinuria presented at American Diabetes Association's 79th Scientific Sessions®
The charts of the maker of recreational vehicles are bearish, while the drugmaker appears to be a buy
REWIND data showed a consistent effect in people with and without established cardiovascular disease
Pivotal phase 3 data in people with type 1 and type 2 diabetes presented at the American Diabetes Association's® 79th Scientific Sessions®
It was a great week for stocks, says Jim Cramer. And he's got your game plan for next week.
INDIANAPOLIS, June 8, 2019 /PRNewswire/ -- Results from several studies of Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist (RA), tirzepatide, reinforce its potential in lowering A1C and body weight in people with...
Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?
- Thirty abstracts will reflect investigations into the treatment of a broad range of rheumatic diseases -
Eli Lilly's plan to eliminate pain could have farther reaching positive effects than just migraines.
- Eighteen abstracts will reveal new insights for the management of moderate-to-severe plaque psoriasis and psoriatic arthritis, as well as the potential treatment of moderate-to-severe atopic dermatitis and alopecia areata -
A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.
-With this approval, Emgality is the only calcitonin gene-related peptide (CGRP) antibody indicated for the preventive treatment of migraine and the treatment of episodic cluster headache
Key oscillator signal works again, but that's no reason to nod off, Jim Cramer says.
RIDGEFIELD, Conn. and INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- The U.
Lilly, Healthcare Ready and Direct Relief Helping People Prepare for Disasters, Ensure Medicines are Available
INDIANAPOLIS, May 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 40 th Annual Global Healthcare Conference on Wednesday, June 12, 2019.
INDIANAPOLIS, May 29, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, June 10, 2019 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's 79th Scientific Sessions...
INDIANAPOLIS, May 28, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid,...
List price of Lilly's Insulin Lispro Injection 50 percent less than branded Humalog
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CG, GMRE, ISSC, JCI, MKL, NFBK, SUN Downgrades: AAOI, AAON, ACIW, CRCM, ENV, LLY, MOS, OFIX, PAGP, PYX, RGNX, SAIL, TTD Initiations: CLNC, VBLT Read on to get TheStreet Quant Ratings' detailed report:
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
The company expects fiscal-year adjusted earnings of $5.60 to $5.70 a share.
U.S. stock futures are mixed after Alphabet posts its weakest revenue gains since 2016; Apple, Advanced Micro Devices, General Electric and General Motors report earnings; BP's first-quarter profit tops forecasts.
Eli Lilly's drug for treating axial spondyloarthritis, a chronic inflammatory disease affecting predominantly the sacroiliac joints and the axial skeleton, meets both primary and secondary endpoints in a Phase 3 study.
This health care selloff shows the value of diversification to protect our portfolios -- and to go on the offensive and find bargains.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.